KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Non Operating Income (2020 - 2023)

AbCellera Biologics' Non Operating Income history spans 4 years, with the latest figure at $59.5 million for Q4 2023.

  • For the quarter ending Q4 2023, Non Operating Income rose 1674.7% year-over-year to $59.5 million, compared with a TTM value of $63.2 million through Dec 2023, up 1233.97%, and an annual FY2024 reading of $114.4 million, up 81.03% over the prior year.
  • Non Operating Income for Q4 2023 was $59.5 million at AbCellera Biologics, up from $2.0 million in the prior quarter.
  • The five-year high for Non Operating Income was $59.5 million in Q4 2023, with the low at -$17.7 million in Q4 2021.
  • Average Non Operating Income over 4 years is $3.4 million, with a median of $1.3 million recorded in 2022.
  • Biggest YoY gain for Non Operating Income was 1792.83% in 2021; the steepest drop was 442.52% in 2021.
  • Tracing ABCL's Non Operating Income over 4 years: stood at -$3.3 million in 2020, then plummeted by 442.52% to -$17.7 million in 2021, then surged by 78.6% to -$3.8 million in 2022, then surged by 1674.7% to $59.5 million in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Non Operating Income are $59.5 million (Q4 2023), $2.0 million (Q3 2023), and -$2.0 million (Q2 2023).